Table 4.

LNG does not impede antiviral activity of APIs included in MZC combination

	IC50 (95% confidence interval)
Compound*	Anti-HIV (nM for MIV-150, μm for ZA)	Anti-HSV-2 (μg/mL)	Anti-HPV (ng/mL)
MIV-150	1.03 (0.79-1.34)	n/a	n/a
MIV-150 + LNG	0.60 (0.32-1.13)	n/a	n/a
CG	n/a	0.010 (0.007-0.014)¶	22.8 (18.2-22.5)
CG+LNG	n/a	0.008 (0.004-0.010)¶	11.5 (10.3-12.8)
ZA	57.6 (29.9-110.8)	18.5 (14.3 to 23.9)	n/a
ZA+LNG	71.9 (43.5-119)	13.6 (10.6-17.5)	n/a
ZA+MIV-150	20.7 (10.9-39.5)	n/a	n/a
ZA+MIV-150+LNG	30.1 (23.7-38.2)	n/a	n/a
CG+ZA	n/d	0.006 (0.006-0.007)¶	n/d
CG+ZA+LNG	n/d	0.005 (0.005-0.006)¶	n/d

^*IC₅₀ values are for the underlined compound;

^¶CG anti-HSV-2 IC₅₀ values are different from those shown in Figure 5 because in this Table virus and compound were pre-incubated before adding to cells while in Figure 5 were added at once to cells; n/a=not applicable; n/d=not determined